Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 48 min ago
Peer-reviewedCC BY-NC 4.0BMJ Case Reports

Marked reduction in serum uric acid levels after empagliflozin initiation in a patient with heart failure

  1. 1Department of Cardiology, Dokkyo Medical University Nikko Medical Center, Nikko, Tochigi, Japan
  2. 2Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, Yufu, Oita, Japan
  3. 3Department of Cardiovascular Medicine and Nephrology, Dokkyo Medical University Nikko Medical Center, Nikko, Tochigi, Japan

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce serum uric acid levels through enhanced urinary excretion; however, individual responses vary. We report the case of a man in his late 60s with heart failure with reduced ejection fraction who experienced a marked reduction in serum uric acid to 3 mg/dL after the initiation of empagliflozin 10 mg daily. This reduction was accompanied by an increase in the fractional excretion of uric acid from 2.89% to 6.59%. Uric acid reduction was sustained during follow-up without clinically relevant adverse events and the patient remained clinically stable. Background urate-lowering therapy remained unchanged before and throughout SGLT2 inhibitor treatment, and no changes were made to concomitant medications during follow-up. SGLT2 inhibitor use may lead to a substantial reduction in serum uric acid levels in select patients and enhanced urinary uric acid excretion may contribute to this effect.

Related

  1. Reduction in Rheumatoid Factor and Matrix Metalloproteinase-3 With Successful Glucocorticoid Withdrawal After Initiation of Pemafibrate in a Patient With Rheumatoid Arthritis and Hypertriglyceridemia: A Case Report.
    Kimihiro Suzuki
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Trends in the Prescribed Doses of Loop Diuretics in Patients With Heart Failure Prescribed Dapagliflozin or Empagliflozin in Japan: An Interrupted Time Series Analysis.
    Ryosuke Miura, Kouji Okada
    Circulation reportsPeer-reviewedCC BY-NC-NDFull textCardiovascular medicineEurope PMCPMC
  3. Kidney function decline, heart failure hospitalization, and the effect of empagliflozin in heart failure: an EMPEROR-pooled analysis
    Masatake Kobayashi, Kévin Duarte, Guillaume Baudry +5
    European Journal of Heart FailurePeer-reviewedCC BY 4.0Full textCardiovascular medicineHAL
  4. Marked reduction of homogentisic acid with nitisinone in a child with alkaptonuria: a case report
    Hossein Emad Momtaz, Maryam Darabi, Nasibeh Ghalandari
    BMC PediatricsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
  5. Marked Monocytic Erythrophagocytosis in a Patient With Cold Agglutinin Disease.
    Tran B Nguyen, Eric D Carlsen, Luis F Carrillo
    EJHaemPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
BibTeX
@article{otani2026marked,
  title = {{Marked reduction in serum uric acid levels after empagliflozin initiation in a patient with heart failure}},
  author = {Naoyuki Otani and Takushi Sugiyama and Yasuhiro Maejima},
  journal = {BMJ Case Reports},
  year = {2026},
  month = nov,
  doi = {10.1136/bcr-2026-275554},
  url = {https://doi.org/10.1136/bcr-2026-275554},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Marked reduction in serum uric acid levels after empagliflozin initiation in a patient with heart failure
AU  - Naoyuki Otani
AU  - Takushi Sugiyama
AU  - Yasuhiro Maejima
PY  - 2026
DA  - 2026/11/05
JO  - BMJ Case Reports
DO  - 10.1136/bcr-2026-275554
UR  - https://doi.org/10.1136/bcr-2026-275554
AB  - Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce serum uric acid levels through enhanced urinary excretion; however, individual responses vary. We report the case of a man in his late 60s with heart failure with reduced ejection fraction who experienced a marked reduction in serum uric acid to 3 mg/dL after the initiation of empagliflozin 10 mg daily. This reduction was accompanied by an increase in the fractional excretion of uric acid from 2.89% to 6.59%. Uric acid reduction was sustained during follow-up without clinically relevant adverse events and the patient remained clinically stable. Background urate-lowering therapy remained unchanged before and throughout SGLT2 inhibitor treatment, and no changes were made to concomitant medications during follow-up. SGLT2 inhibitor use may lead to a substantial reduction in serum uric acid levels in select patients and enhanced urinary uric acid excretion may contribute to this effect.
SN  - 1757-790X
ER  -